Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A 2-Gene Host Signature for Improved Accuracy of COVID-19 Diagnosis Agnostic to Viral Variants

ABSTRACT: A 2-Gene Host Signature for Improved Accuracy of COVID-19 Diagnosis Agnostic to Viral Variants

PROVIDER: PRJNA779935 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A 2-Gene Host Signature for Improved Accuracy of COVID-19 Diagnosis Agnostic to Viral Variants

Project description:The continued emergence of SARS-CoV-2 variants is one of several factors that may cause false negative viral PCR test results. Such tests are also susceptible to false positive results due to trace contamination from high viral titer samples. Host immune response markers provide an orthogonal indication of infection that can mitigate these concerns when combined with direct viral detection. Here, we leverage nasopharyngeal swab RNA-seq data from patients with COVID-19, other viral acute respiratory illnesses and non-viral conditions (n=318) to develop support vector machine classifiers that rely on a parsimonious 2-gene host signature to diagnose COVID-19. We find that optimal classifiers include an interferon-stimulated gene that is strongly induced in COVID-19 compared with non-viral conditions, such as IFI6, and a second immune-response gene that is more strongly induced in other viral infections, such as GBP5. The IFI6+GBP5 classifier achieves an area under the receiver operating characteristic curve (AUC) greater than 0.9 when evaluated on an independent RNA-seq cohort (n=553). We further provide proof-of-concept demonstration that the classifier can be implemented in a clinically relevant RT-qPCR assay. Finally, we show that its performance is robust across common SARS-CoV-2 variants and is unaffected by cross-contamination, demonstrating its utility for improving accuracy of COVID-19 diagnostics.

2021-11-15 | GSE188678 | GEO

A 2-Gene Host Signature for Improved Accuracy of COVID-19 Diagnosis Agnostic to Viral Variants.

Project description: Not available

| S-EPMC9948727 | biostudies-literature

Assessing the Accuracy of a blood RNA biomarker for diagnosis of Alzheimer's Disease

Project description:Assessing the Accuracy of a blood RNA biomarker for diagnosis of Alzheimer's Disease

| PRJNA1366574 | ENA

Assessing the Accuracy of a blood RNA biomarker for diagnosis of Alzheimer's Disease

Project description:Assessing the Accuracy of a blood RNA biomarker for diagnosis of Alzheimer's Disease

| PRJNA1366573 | ENA

A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine Tumors

Project description:A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine Tumors

| PRJNA515771 | ENA

A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine Tumors

Project description:A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine Tumors

| PRJNA515772 | ENA

Leveraging the pulmonary immune response and microbiome for improved lower respiratory tract infection diagnosis in critically ill children

Project description:BACKGROUND. Lower respiratory tract infection (LRTI) is a leading cause of death in children worldwide. LRTI diagnosis is challenging since non-infectious respiratory illnesses appear clinically similar and existing microbiologic tests are often falsely negative or detect incidentally-carried microbes common in children. These challenges result in antimicrobial overuse and adverse patient outcomes. Lower airway metagenomics has the potential to detect host and microbial signatures of LRTI. Whether it can be applied at scale and in a pediatric population to enable improved diagnosis and precision treatment remains unclear. METHODS. We used tracheal aspirate RNA-sequencing to profile host gene expression and respiratory microbiota in 261 children with acute respiratory failure. We developed a random forest gene expression classifier for LRTI by training on patients with an established diagnosis of LRTI (n=117) or of non-infectious respiratory failure (n=50). We then developed a classifier that integrates the: i) host LRTI probability, ii) abundance of respiratory viruses, and iii) dominance in the lung microbiome of bacteria/fungi considered pathogenic by a rules-based algorithm. RESULTS. The host classifier achieved a median AUC of 0.967 by 5-fold cross-validation, driven by activation markers of T cells, alveolar macrophages and the interferon response. The integrated classifier achieved a median AUC of 0.986 and significantly increased the confidence of patient classifications. When applied to patients with an uncertain diagnosis (n=94), the integrated classifier indicated LRTI in 52% of cases and nominated likely causal pathogens in 98% of those. CONCLUSIONS. Lower airway metagenomics enables accurate LRTI diagnosis and pathogen identification in a heterogeneous cohort of critically ill children through integration of host, pathogen, and microbiome features.

2022-12-06 | GSE212532 | GEO

An Improved Understanding of the Aetiology and Diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C)

Project description:An Improved Understanding of the Aetiology and Diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C)

| PRJEB107410 | ENA

CapTrap-Seq: A platform-agnostic and quantitative approach for high-fidelity full-length RNA transcript sequencing

Project description:Here we describe CapTrap-Seq, an experimental workflow designed to address the problem of reduced transcript end detection by long-read RNA sequencing methods, especially at the 5' ends. We apply CapTrap-Seq to profile transcriptomes of the human heart and brain and we compared the obtained results with other library preparation approaches. CapTrap-Seq is a platform-agnostic method and here tested the method by using 3 different long-read sequencing platforms: MinION (ONT), Sequel (PacBaio) and Sequel II (PacBio).

2023-12-20 | E-MTAB-13063 | biostudies-arrayexpress

Protein-agnostic pulldown of brain-derived aggregates from Motor Neuron Disease

Project description:Characterisation of homognised BA tissue extracts from TDP-43 MND (Ã—5), SOD1-MND (Ã—2) and neurologically normal controls (Ã—3) using the protein-agnostic aggregate probe CAP1.

2026-02-03 | PXD061429 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data